Overgrowth

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 16, Issue 3, 2002, Pages 519-546

  Ambler, Geoffrey ^a  

^a CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

Author keywords

Height limitation; Macrosomia; Overgrowth; Tall stature

Indexed keywords

ANDROGEN; CONJUGATED ESTROGEN; DIETHYLSTILBESTROL; ESTROGEN; ETHINYLESTRADIOL; GESTAGEN; GROWTH HORMONE; HORMONE; LONG ACTING DRUG; MEDROXYPROGESTERONE; OCTREOTIDE; PROPRANOLOL; PYRIDOXINE; SEX HORMONE; SOMATOMEDIN; SOMATOMEDIN B; SOMATOSTATIN DERIVATIVE; TESTOSTERONE; TESTOSTERONE ENANTATE; TESTOSTERONE ESTER; TESTOSTERONE UNDECANOATE;

ACNE; AGGRESSION; BECKWITH WIEDEMANN SYNDROME; BODY HEIGHT; BREAST DISEASE; CHROMOSOME ABERRATION; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DOSE RESPONSE; DRUG EFFECT; ELEJALDE SYNDROME; ENDOCRINE DISEASE; ENDOMETRIOSIS; FETUS GROWTH; GENE INTERACTION; GENETIC DISORDER; GENOTYPE ENVIRONMENT INTERACTION; GIGANTISM; GROWTH DISORDER; GROWTH REGULATION; GYNECOLOGIC DISEASE; GYNECOMASTIA; HEADACHE; HOMOCYSTINURIA; HORMONE DEFICIENCY; HORMONE RECEPTOR INTERACTION; HUMAN; HYPERINSULINISM; HYPERTHYROIDISM; HYPOGLYCEMIA; INFANCY; LIVER TOXICITY; LONG TERM CARE; LOW DRUG DOSE; MACROSOMIA; MARFAN SYNDROME; MARSHALL SYNDROME; NAUSEA; NEUROFIBROMATOSIS; NEVO SYNDROME; OBESITY; OVARY CYST; PERLMAN SYNDROME; POSTNATAL GROWTH; PRECOCIOUS PUBERTY; PREDICTION; PRENATAL GROWTH; REVIEW; SEXUAL BEHAVIOR; SHORT STATURE; SIDE EFFECT; SIMPSON GOLABI BEHMEL SYNDROME; SOTOS SYNDROME; SPERM; SPONTANEOUS ABORTION; STEROID THERAPY; TALL STATURE; TESTIS SIZE; VAGINA DISCHARGE; VERTIGO; WEAVER SYNDROME; WEIGHT GAIN; ACROCEPHALOSYNDACTYLY; ENVIRONMENTAL FACTOR; HEREDITY; HORMONE ACTION; LIVER DISEASE; PERSISTENT HYPERINSULINEMIC HYPOGLYCEMIA OF INFANCY;

EID: 0036428301     PISSN: 1521690X     EISSN: None     Source Type: Journal    
DOI: 10.1053/beem.2002.0207     Document Type: Article

References (173)

1. Sotos JF. Overgrowth disorders. Clinical Pediatrics (Philadelphia) 1996; 35: 517-529.
2. Gluckman PD. Endocrine and nutritional regulation of prenatal growth. Acta Paediatrica 1997; 423 (supplement): 153-157.
3. Milner RDG. Growth: prenatal growth control. In Gluckman PD & Heymann MA (eds) Perinatal and Pediatric Pathophysiology: a Clinical Perspective pp 153-190. London: Edward Arnold, 1993.
4. Hill DJ, Petrik J & Arany E. Growth factors and the regulation of fetal growth. Diabetes Care 1998; 21 (supplment 2): B60-B69.
5. D'Ercole AJ. Mechanisms of in utero overgrowth. Acta Paediatrica 1999; 88 (supplment): 31-36.
6. Butler AA & LeRoith D. Minireview: tissue-specific versus generalized gene targeting of the igfl and igflr genes and their roles in insulin-like growth factor physiology. Endocrinology 2001; 142: 1685-1688.
7. Chernausek S. Insulin-like growth factor control of growth: insights from targeted disruption of murine genes and from human disease. In Handwerger S (ed.) Molecular and Cellular Pediatric Endocrinology pp 11-22. Totowa, New Jersey: Humana Press, 1999.
8. Sun FL, Dean WL, Kelsey G et al. Transactivation of Igf2 in a mouse model of Beckwith-Wiedemann syndrome. Nature 1997; 389: 809-815.
9. Ludwig T, Eggenschwiler J, Fisher P et al. Mouse mutants lacking the type 2 IGF receptor (IGF2R) are rescued from perinatal lethality in Igf2 and Igflr null backgrounds. Developmental Biology 1996; 177: 517-535.
10. Lau MM, Stewart CE, Liu Z et al. Loss of the imprinted IGF2/cation-independent mannose 6-phosphate receptor results in fetal overgrowth and perinatal lethality. Genes & Development 1994; 8: 2953-2963.
11. Deng C, Wynshaw-Boris A, Zhou F et al. Fibroblast growth factor receptor 3 is a negative regulator of bone growth. Cell 1996; 84: 911-921.
12. Partington MW, Fagan K, Soubjaki V & Turner G. Translocations involving 4p16.3 in three families: deletion causing the Pitt-Rogers-Danks syndrome and duplication resulting in a new overgrowth syndrome. Journal of Medical Genetics 1997; 34: 719-728.
13. Webber AL, Ingram RS, Levorse JM & Tilghman SM. Location of enhancers is essential for the imprinting of H19 and Igf2 genes. Nature 1998; 391: 711-715.
14. Gourmelen M, Le Bouc Y, Girard F & Binoux M. Serum levels of insulin-like growth factor (IGF) and IGF binding protein in constitutionally tall children and adolescents. Journal of Clinical Endocrinology and Metabolism 1984; 59: 1197-1203.
15. Smith EP, Boyd J, Frank GR et al. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. New England Journal of Medicine 1994; 331: 1056-1061.
16. Morishima A, Grumbach MM, Simpson ER et al. Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. Journal of Clinical Endocrinology and Metabolism 1995; 80: 3689-3698.
17. Rao E, Weiss B, Fukami M et al. Pseudoautosomal deletions encompassing a novel homeobox gene cause growth failure in idiopathic short stature and Turner syndrome. Nature Genetics 1997; 16: 54-63.
18. Ellison JW, Wardak Z, Young MF et al. PHOG, a candidate gene for involvement in the short stature of Turner syndrome. Human Molecular Genetics 1997; 6: 1341-1347.
19. Ogata T, Matsuo N & Nishimura G. SHOX haploinsufficiency and overdosage: impact of gonadal function status. Journal of Medical Genetics 2001; 38: 1-6.
20. Binder G, Eggermann T, Enders H et al. Tall stature, gonadal dysgenesis, and stigmata of Turner's syndrome caused by a structurally altered X chromosome. Journal of Pediatrics 2001; 138: 285-287.
21. Ellis JA, Stebbing M & Harrap SB. Significant population variation in adult male height associated with the Y chromosome and the aromatase gene. Journal of Clinical Endocrinology and Metabolism 2001; 86: 4147-4150.
22. Kuczmarski RJ, Ogden CL, Grummer-Strawn LM, et al. CDC growth charts: United States. Advance Data 2000; 314: 1-27.
23. Cohen MM Jr, Neri G & Weksberg R. Maternal and endocrine effects. Overgrowth Syndromes pp 180-188. Oxford: Oxford University Press, 2002.
24. Kuhns LR & Holt JF. Measurement of thoracic spine length on chest radiographs of newborn infants. Radiology 1975; 116: 395-197.
25. Djelmis J, Bukovic D, Pfeifer D & Ivanisevic M. Ponderal index and disproportionate fetal growth in IDDM pregnancies. Collegium antropologicum 1998; 22: 491-495.
26. Ballard JL, Rosenn B, Khoury JC & Miodovnik M. Diabetic fetal macrosomia: significance of disproportionate growth. Journal of Pediatrics 1993; 122: 115-119.
27. Martinez-Frias ML. Epidemiological analysis of outcomes of pregnancy in diabetic mothers: identification of the most characteristic and most frequent congenital anomalies. American Journal of Medical Genetics 1994; 51: 108-113.
28. Neave C. Congenital malformation in offspring of diabetics. Perspectives in Pediatric Pathology 1984; 8: 213-222.
29. Tyrell VJ, Ambler GR, Yeow W-H et al. Ten years' experience of persistent hyperinsulinaemic hypoglycemia of infancy. Journal of Paediatrics and Child Health 2001; 37: 483-488.
30. Mathew PM, Young JM, Abu-Osba YK et al. Persistent neonatal hyperinsulinism. Clinical Pediatrics (Philadelphia) 1988; 27: 148-151.
31. Weaver DD, Graham CB, Thomas IT & Smith DW. A new overgrowth syndrome with accelerated skeletal maturation, unusual facies, and camptodactyly. Journal of Pediatrics 1974; 84: 547-552.
32. Dunne MJ, Kane C, Shepherd RM et al. Familial persistent hyperinsulinemic hypoglycemia of infancy and mutations in the sulfonylurea receptor. New England Journal of Medicine 1997; 336: 703-706.
33. Thomas PM, Wohllk N, Huang E et al. Inactivation of the first nucleotide-binding fold of the sulfonylurea receptor, and familial persistent hyperinsulinemic hypoglycemia of infancy. American Journal of Human Genetics 1996; 59: 510-518.
34. Sharon M, Cassoria FG, Rose SR & Loriaux DL. Edema associated with improved glycemic control in an adolescent with type 1 diabetes. Journal of Pediatrics 1987; 111: 403-404.
35. Dunne MJ, Kane C, Shepherd RM et al. Familial persistent hyperinsulinemic hypoglycemia of infancy and mutations in the sulfonylurea receptor. New England Journal of Medicine 1997; 336: 703-706.
36. Inagaki N, Gonoi T, Clement JP et al. Reconstitution of IKATP: an inward rectifier subunit plus the sulfonylurea receptor (see comments). Science 1995; 270: 1166-1170.
37. Verkarre V, Fournet JC, De Lonlay P et al. Paternal mutation of the sulfonylurea receptor (SURI) gene and maternal loss of 11p15 imprinted genes lead to persistent hyperinsulinism in focal adenomatous hyperplasia. Journal of Clinical Investigation 1998; 102: 1286-1291.
38. Thornton PS, Satin-Smith MS, Herold K et al. Familial hyperinsulinism with apparent autosomal dominant inheritance: clinical and genetic differences from the autosomal recessive variant (see comments). Journal of Pediatrics 1998; 132: 9-14.
39. Glaser B, Kesavan P, Heyman M et al. Familial hyperinsulinism caused by an activating glucokinase mutation. New England Journal of Medicine 1998; 338 226-230.
40. Stanley CA, Lieu YK, Hsu BY et al. Hyperinsulinism and hyperammonemia in infants with regulatory mutations of the glutamate dehydrogenase gene. New England Journal of Medicine 1998; 338: 1352-1357.
41. Thornton PS, Satin-Smith MS, Herold K et al. Familial hyperinsulinism with apparent autosomal dominant inheritance: clinical and genetic differences from the autosomal recessive variant. Journal of Pediatrics 1998; 132: 9-14.
42. Sotos JF. Overgrowth. Section VI. Genetic syndromes and other disorders associated with overgrowth. Clinical Pediatrics (Philadelphia) 1997; 36: 157-170.
43. Cohen MM Jr, Neri G & Weksberg R. Beckwith-Widemann syndrome. Overgrowth Syndromes pp 11-31. Oxford: Oxford University Press, 2002.
44. Pettenati MJ, Haines JL, Higgins RR et al. Wiedemann-Beckwith syndrome: presentation of clinical and cytogenetic data on 22 new cases and review of the literature. Human Genetics 1986; 74: 143-154.
45. Maher ER & Reik W. et al. Beckwith-Wiedemann syndrome: imprinting inclusters revisited. Journal of Clinical Investigation 2000; 105(3): 247-252.
46. Li M, Squire JA & Weksberg R. Molecular genetics of Wiedemann-Beckwith syndrome. American Journal of Medical Genetics 1998; 79: 253-259.
47. Weksberg R, Shen DR, Fei YL et al. Disruption of insulin-like growth factor 2 imprinting in Beckwith-Wiedemann syndrome. Nature Genetics 1993; 5: 143-150.
48. Weng EY, Moeschler JB & Graham JM Jr. Longitudinal observations on 15 children with Wiedemann-Beckwith syndrome. American Journal of Medical Genetics 1995; 56: 366-373.
49. Elliott M, Bayly R, Cole T et al. Clinical features and natural history of Beckwith-Wiedemann syndrome: presentation of 74 new cases. Clinical Genetics 1994; 46: 168-174.
50. Engstrom W, Lindham S & Schofield P. Wiedemann-Beckwith syndrome. European Journal of Pediatrics 1988; 147: 450-457.
51. Wiedemann HR. Frequency of Wiedemann-Beckwith syndrome in Germany; rate of hemihyperplasia and of tumours in affected children. European Journal of Pediatrics 1997; 156: 251.
52. Neri G, Marini R, Cappa M et al. Simpson-Golabi-Behmel syndrome: an X-linked encephalo-trophoschisis syndrome. American Journal of Medical Genetics 1988; 30; 287-299.
53. Hughes-Benzie R, Allanson J, Hunter A & Cole T. The importance of differentiating Simpson-Golabi-Behmel and Beckwith-Wiedemann syndromes. Journal of Medical Genetics 1992; 29: 928.
54. Pilia G, Hughes-Benzie RM, MacKenzie A et al. Mutations in GPC3, a glypican gene, cause the Simpson-Golabi-Behmel overgrowth syndrome. Nature Genetics 1996; 12: 241-247.
55. Weksberg R, Squire JA & Templeton DM. Glypicans: a growing trend. Nature Genetics 1996; 12: 225-227.
56. Perlman M. Perlman syndrome: familial renal dysplasia with Wilms tumor, fetal gigantism, and multiple congenital anomalies. American Journal of Medical Genetics 1986; 25: 793-795.
57. Opitz JM, Weaver DW & Reynolds JF Jr. The syndromes of Sotos and Weaver: reports and review. American Journal of Medical Genetics 1998; 79: 294-304.
58. Marshall RE, Graham CB, Scott CR & Smith DW. Syndrome of accelerated skeletal maturation and relative failure to thrive: a newly recognized clinical growth disorder. Journal of Pediatrics 1971; 78: 95-101.
59. Cohen MM Jr, Neri G & Weksberg R. Nonsyndromal overgrowth. Overgrowth syndromes pp 193-199. Oxford: Oxford University Press, 2002.
60. Elejalde BR, Giraldo C, Jimenez R & Gilbert EF. Acrocephalopolydactylous dysplasia. Birth Defects Original Article Series 1977; 13(3B): 53-67.
61. Nevo S, Zeltzer M, Benderly A & Levy J. Evidence for autosomal recessive inheritance in cerebral gigantism. Journal of Medical Genetics 1974; 11: 158-165.
62. Cohen MM. Diagnostic problems in cerebral gigantism (letter) Journal of Medical Genetics 1976; 13: 80.
63. Hindmarsh PC & Brook CG. Tall stature. In Brook CGD (ed.) Clinical Paediatric Endocrinology pp 195-209. Oxford: Blackwell Science Ltd, 1993.
64. Hochberg Z & Ritzen M. Tall stature. In Hochberg Z (ed.) Practical Algorithms in Pediatric Endocrinology. Basel: Karger, 1999.
65. Drop SL, de Waal WJ & de Muinck Keizer-Schrama SM. Sex steroid treatment of constitutionally tall stature. Endocrinology Reviews 1998; 19: 540-558.
66. Harrap SB, Stebbing M, Hopper JL et al. Familial patterns of covariation for cardiovascular risk factors in adults: The Victorian Family Heart Study. American Journal of Epidemiology 2000; 152: 704-715.
67. Albertsson-Wikland K & Rosberg S. Analyses of 24-hour growth hormone profiles in children: relation to growth. Journal of Clinical Endocrinology and Metabolism 1988; 67: 493-500.
68. Rochiccioli P, Messina A, Tauber MT & Enjaume C. Correlation of the parameters of 24-hour growth hormone secretion with growth velocity in 93 children of varying height. Hormone Research 1989; 31: 115-118.
69. Blum WF, Albertsson-Wikland K, Rosberg S & Ranke MB. Serum levels of insulin-like growth factor I (IGF-I) and IGF binding protein 3 reflect spontaneous growth hormone secretion. Journal of Clinical Endocrinology and Metabolism 1993; 76: 1610-1616.
70. Tauber M, Pienkowski C & Rochiccioli P. Growth hormone secretion in children and adolescents with familial tall stature. European Journal of Pediatrics 1994; 153: 311-316.
71. Dickerman Z, Loewinger J & Laron Z. The pattern of growth in children with constitutional tall stature from birth to age 9 years. A longitudinal study. Acta Paediatrica Scandinavica 1984; 73: 530-536.
72. Skogland LB, Steen H & Trygstad O. Spinal deformities in tall girls. Acta Orthopaedica Scandinavica 1985; 56: 155-157.
73. Hensley WE & Cooper R. Height and occupational success: a review and critique. Psychology Reports 1987; 60: 843-849.
74. Teasdale TW, Owen DR & Sorensen TI. Intelligence and educational level in adult males at the extremes of stature. Human Biology 1991; 63: 19-30.
75. Binder G, Grauer ML, Wehner AV et al. Outcome in tall stature. Final height and psychological aspects in 220 patients with and without treatment. European Journal of Pediatrics 1997; 156: 905-910.
76. Wettenhall HN, Cahill C & Roche AF. Tall girls: a survey of 15 years of management and treatment. Journal of Pediatrics 1975; 86: 602-610.
77. Prader A & Zachmann M. Treatment of excessively tall girls and boys with sex hormones. Pediatrics 1978; 62: 1202-1210.
78. Bailey JD, Park E & Cowell C. Estrogen treatment of girls and constitutional tall stature. Pediatric Clinics of North America 1981; 28: 501-512.
79. Bayley N. Tables for predicting adult height from skeletal age: revised for use with the Greulich-Pyle hand standards. Journal of Pediatrics 1952; 40: 432-441.
80. Tanner JM, Whitehouse RH, Cameron N et al. Assessment of Skeletal Maturity and Prediction of Adult Height (TW2 Method). New York: Academic Press, 1983.
81. de Waal WJ, Greyn-Fokker MH, Stijnen T et al. Accuracy of final height prediction and effect of growth-reductive therapy in 362 constitutionally tall children. Journal of Clinical Endocrinology and Metabolism 1996; 81: 1206-1216.
82. de Waal WJ, Stijnen T, Lucas IS et al. A new model to predict final height in constitutionally tall children. Acta Paediatrica 1996; 85: 889-893.
83. Frank GR. The role of estrogen in pubertal skeletal physiology: epiphyseal maturation and mineralization of the skeleton. Acta Paediatrica 1995; 84: 627-630.
84. Zachmann M, Ferrandez A, Murset G et al. Testosterone treatment of excessively tall boys. Journal of Pediatrics 1976; 88: 116-123.
85. Bramswig JH, Schellong G, Borger HJ & Breu H. [Testosteron treatment of excessively tall boys (author's transl)]. Deutsche Medizinische Wochenschrift 1981; 106: 1656-1661.
86. Bramswig JH, von Lengerke HJ, Schmidt H & Schellong G. The results of short-term (6 months) high-dose testosterone treatment on bone age and adult height in boys of excessively tall stature. European Journal of Pediatrics 1988; 148: 104-106.
87. Martin MM, Martin AL & Mossman KL. Testosterone treatment of constitutional delay in growth and development: effect of dose on predicted versus definitive height. Acta Endocrinologica (Copenhagen) 1986; 279(supplement): 147-152.
88. de Waal WJ, Vreeburg JT, Bekkering F et al. High dose testosterone therapy for reduction of final height in constitutionally tall boys: does it influence testicular function in adulthood? Clinical Endocrinology (Oxford) 1995; 43: 87-95.
89. Hanker JP, Schellong G & Schneider HP. The functional state of the hypothalamo-pituitary axis after high-dose oestrogen therapy in excessively tall girls. Acta Endocrinologica (Copenhagen) 1979; 91: 19-29.
90. de Waal WJ, Torn M, de Muinck Keizer-Schrama et al. Long term sequelae of sex steroid treatment in the management of constitutionally tall stature. Archives of Disease in Childhood 1995; 73: 311-315.
91. France D. Tall girls. Newsweek. MSNB.com, February 5, 2002.
92. Svan H, Ritzen EM, Hall K & Johansson L. Estrogen treatment of tall girls: dose dependency of effects on subsequent growth and IGF-I levels in blood. Acta Paediatrica Scandinavica 1991; 80: 328-332.
93. Normann EK, Trygstad O, Larsen S & Dahl-Jorgensen K. Height reduction in 539 tall girls treated with three different dosages of ethinyloestradiol. Archives of Disease in Childhood 1991; 66: 1275-1278.
94. Plaschaert VF, van der Eijken JW, Odink RJ et al. Bilateral epiphysiodesis around the knee as treatment for excessive height in boys. Journal of Pediatric Orthopedics 1997; 6: 212-214.
95. Drop SL, Greggio N, Cappa M & Bernasconi S. Current concepts in tall stature and overgrowth syndromes. Journal of Pediatric Endocrinology and Metabolism 2001; 14 (supplement 2): 975-984.
96. Barnard ND, Scialli AR & Boccara JF. The current use of estrogens for growth-suppressant therapy in adolescent girls. Journal of Pediatric Endocrinology 2000 (in press)
97. Vignolo M, Naselli A, Di Battista E et al. Growth and development in simple obesity. European Journal of Pediatrics 1988; 147: 242-244.
98. Boutin P & Froguel P. Genetics of human obesity. Baillière's Clinical Endocrinology and Metabolism 2001; 15: 391-404.
99. Loche S, Cappa M, Borrelli P et al. Reduced growth hormone response to growth hormone-releasing hormone in children with simple obesity: evidence for somatomedin-C mediated inhibition. Clinical Endocrinology (Oxford) 1987; 27: 145-153.
100. Chen D & Garg A. Monogenic disorders of obesity and body fat distribution. Journal of Lipid Research 1999; 40: 1735-1746.
101. Montague CT, Farooqi IS, Whitehead JP et al. Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature 1997; 387: 903-908.
102. Strobel S, Issad T, Camoin L et al. A leptin missense mutation associated with hypogonadism and morbid obesity. Nature Genetics 1998; 18: 213-215.
103. Clement K, Vaisse C, Lahlou N, et al. A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction. Nature 1998; 392: 398-401.
104. Jackson RS, Creemers JW, Ohagi S et al. Obesity and impaired prohormone processing associated with mutations in the human prohormone covertase I gene. Nature Genetics 1997; 16: 303-306.
105. Krude H, Biebermann H, Luck W et al. Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans. Nature Genetics 1998; 19: 155-157.
106. Vaisse C, Clement K, Durand E et al. Melanocortin-4 receptor mutations are a frequent and heterogeneous cause of morbid obesity. Journal of Clinical Investigation 2000; 106: 253-262.
107. Farooqi IS, Yeo GS, Keogh JM et al. Dominant and recessive inheritance of morbid obesity associated with melanocortin 4 receptor deficiency. Journal of Clinical Investigation 2000; 106: 271-279.
108. Quabbe H-J & Plockinger U. Somatotroph adenomas: acromegaly and gigantism. In Thapar K, Kovacs K, Scheithauer BW & Lloyd RV (eds) Diagnosis and Management of Pituitary Tumours pp 295-316. Totowa, New Jersey: Humana Press, 2001.
109. Behrens LH & Barr DP. Hypopituitarism beginning in infancy: The Alton Giant. Endocrinology 1932; 16: 120.
110. Daughaday WH. Pituitary gigantism. Endocrinology and Metabolism Clinics of North America 1992; 21: 633-647.
111. Zimmerman D, Young WF Jr, Ebersold MJ et al. Congenital gigantism due to growth hormone-releasing hormone excess and pituitary hyperplasia with adenomatous transformation. Journal of Clinical Endocrinology and Metabolism 1993; 76: 216-222.
112. Gadelha MR, Une KN, Rohde K et al. Isolated familial somatotropinomas: establishment of linkage to chromosome 11q13-1-11q13.3 and evidence for a potential second locus at chromosome 2p16-12. Journal of Clinical Endocrinology and Metabolism 2000; 85: 707-714.
113. Lofqvist C, Andersson E, Gelander L et al. Reference values for IGF-I throughout childhood and adolescence: a model that accounts simultaneously for the effect of gender, age, and puberty. Journal of Clinical Endocrinology and Metabolism 2001; 86: 5870-5876.
114. Juul A, Dalgaard P, Blum WF et al. Serum levels of insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) in healthy infants, children, and adolescents: the relation to IGF-I, IGF-II, IGFBP-1, IGFBP-2, age, sex, body mass index, and pubertal maturation. Journal of Clinical Endocrinology and Metabolism 1995; 80: 2534-2542.
115. Holl RW, Bucher P, Sorgo W et al. Suppression of growth hormone by oral glucose in the evaluation of tall stature. Hormone Research 1999; 51: 20-24.
116. Lu PW, Silink M, Johnston I, Cowell CT & Jimenez M. Pituitary gigantism. Archives of Disease in Childhood 1992; 67: 1039-1041.
117. Bilezikian JP, Morishima A, Bell J & Grumbach MM. Increased bone mass as a result of estrogen therapy in a man with aromatase deficiency. New England Journal of Medicine 1998; 339: 599-603.
118. Carani C, Qin K, Simoni M et al. Effect of testosterone and estradiol in a man with aromatase deficiency. New England Journal of Medicine 1997; 337: 91-95.
119. Bhasin S, Ma K, Sinha I et al. The genetic basis of male infertility. Endocrinology and Metabolism Clinics of North America 1998; 27: 783-805, viii.
120. Hamerton JL, Canning N, Ray M & Smith S. A cytogenetic survey of 14,069 newborn infants. I. Incidence of chromosome abnormalities. Clinical Genetics 1975; 8: 223-243.
121. Jacobs PA, Melville M, Ratcliffe S et al. A cytogenetic survey of 11,680 newborn infants. Annals of Human Genetics 1974; 37: 359-376.
122. Ratcliffe SG, Butler GE & Jones M. Edinburgh study of growth and development of children with sex chromosome abnormalities. IV. Birth Defects Original Article Series 1990; 26: 1-44.
123. Ratcliffe SG, Pan H & McKie M. Growth during puberty in the XYY boy. Annals of Human Biology 1992; 19: 579-587.
124. Stewart DA, Bailey JD, Netley CT et al. Growth and development of children with X and Y chromosome aneuploidy from infancy to pubertal age: the Toronto study. Birth Defects Original Article Series 1982; 18: 99-154.
125. Gabrilove JL, Freiberg EK & Nicolis GL. Testicular function in Klinefelter's syndrome. Journal of Urology 1980; 124: 825-826.
126. Gordon DL, Krmpotic E, Thomas W et al. Pathologic testicular findings in Klinefelter's syndrome 47,XXY vs 46,XY-47,XXY. Archives of Internal Medicine 1972; 130: 726-729.
127. Friedler S, Raziel A, Strassburger D et al. Outcome of ICSI using fresh and cryopreserved-thawed testicular spermatozoa in patients with non-mosaic Klinefelter's syndrome. Human Reproduction 2001; 16: 2616-2620.
128. Poulakis V, Witzsch U, Diehl W et al. Birth of two infants with normal karyotype after intracytoplasmic injection of sperm obtained by testicular extraction from two men with nonmosaic. Klinefelter's syndrome. Fertility and Sterility 2001; 76: 1060-1062.
129. Cruger D, Toft B, Agerholm I et al. Birth of a healthy girl after ICSI with ejaculated spermatozoa from a man with non-mosaic Klinefelter's syndrome. Human Reproduction 2001; 16: 1909-1911.
130. Ratcliffe SG, Bancroft J, Axworthy D & McLaren W. Klinefelter's syndrome in adolescence. Archives of Disease of Childhood 1982; 57: 6-12.
131. Price WH, Clayton JF, Wilson J et al. Causes of death in X chromatin positive males (Klinefelter's syndrome). Journal of Epidemiology and Community Health 1985; 39: 330-336.
132. Schwartz ID & Root AW. The Klinefelter syndrome of testicular dysgenesis. Endocrinology and Metabolism Clinics of North America 1991; 20: 153-163.
133. Nielsen J & Pelsen B. Follow-up 20 years later of 34 Klinefelter males with karyotype 47,XXY and 16 hypogonadal males with karyotype 46,XY. Human Genetics 1987; 77: 188-192.
134. Kleczkowska A, Fryns JP & Van den BH. X-chromosome polysomy in the male. The Leuven experience 1966-1987. Human Genetics 1988; 80: 16-22.
135. Nielsen J, Pelsen B & Sorensen K. Follow-up of 30 Klinefelter males treated with testosterone. Clinical Genetics 1988; 33: 262-269.
136. Paulsen CA, Gordon DL, Carpenter RW et al. Klinefelter's syndrome and its variants: a hormonal and chromosomal study. Recent Progress in Hormone Research 1968; 24: 321-363.
137. Winter JS. Androgen therapy in Klinefelter syndrome during adolescence. Birth Defects Original Article Series 1990; 26: 235-245.
138. Sotos JF. Genetic disorders associated with overgrowth. Clinical Pediatrics (Philadelphia) 1997; 36: 39-49.
139. Ratcliffe SG, Pan H & McKie M. Growth during puberty in the XYY boy. Annals of Human Biology 1992; 19: 579-587.
140. Borgaonkar DS & Shah SA. The xyy chromosome male - or syndrome? Progress in Medical Genetics 1974; 10: 135-222.
141. Robinson A, Bender BG & Linden MG. Summary of clinical findings in children and young adults with sex chromosome anomalies. Birth Defects Original Article Series 1990; 26: 225-228.
142. Stewart DA, Netley CT & Park E. Summary of clinical findings of children with 47,XXY, 47,XYY, and 47,XXX karyotypes. Birth Defects Original Article Series 1982; 18: 1-5.
143. Cohen MM Jr, Neri G & Weksberg R. Chromosomal Disorders with Overgrowth. Overgrowth Syndromes pp 161-165. Oxford: Oxford University Press, 2002.
144. Pyeritz RE & McKusick VA. The Marfan syndrome: diagnosis and management. New England Journal of Medicine 1979; 300: 772-777.
145. Oosterhof T, Groenik M, Hulsman FJ et al. Quantitative assessment of dural ectasia as a marker for Marfan syndrome. Radiology 2001; 220: 514-518.
146. Rose PS, Levy HP, Ahn NU et al. A comparison of the Berlin and Ghent nosologies and the influence of dural ectasia in the diagnosis of Marfan syndrome. Genetic Medicine 2000; 2: 278-282.
147. Buntinx IM, Willems PJ, Spitaels SE et al. Neonatal Marfan syndrome with congenital arachnodactyly, flexion contractures, and severe cardiac valve insufficiency. Journal of Medical Genetics 1991; 28: 267-273.
148. Beighton P, de Paepe A, Danks D et al. International Nosology of Heritable Disorders of Connective Tissue, Berlin, 1986. American Journal of Medical Genetics 1988; 29: 581-594.
149. Robinson PN & Booms P. The molecular pathogenesis of the Marfan syndrome. Cell and Molecular Life Science 2001; 58: 1698-1707.
150. Lipscomb KJ, Clayton-Smith J & Harris R. Evolving phenotype of Marfan's syndrome. Archives of Disease in Childhood 1997; 76: 41-46.
151. Pyeritz RE. Marfan syndrome. Principles and Practice of Medical Genetics. New York: Churchill Livingstone, 1983.
152. Silverman DI, Burton KJ, Gray J et al. Life expectancy in the Marfan syndrome. American Journal of Cardiology 1995; 75: 157-160.
153. Gott VL, Pyeritz RE, Magovern GJ Jr et al. Surgical treatment of aneurysms of the ascending aorta in the Marfan syndrome. Results of composite-graft repair in 50 patients. New England Journal of Medicine 1986; 134: 1070-1074.
154. Gott VL, Greene PS, Alejo DE et al. Replacement of the aortic root in patients with Marfan's syndrome. New England Journal of Medicine 1999; 340: 1307-1313.
155. Shores J, Berger KR, Murphy EA & Pyeritz RE. Progression of aortic dilatation and the benefit of long-term beta-adrenergic blockade in Marfan's syndrome. New England Journal of Medicine 1994; 330: 1335-1341.
156. Beals RK & Hecht F. Congenital contractural arachnodactyly. A heritable disorder of connective tissue. Journal of Bone and Joint Surgery (Am) 1971; 53: 987-993.
157. Gupta PA, Putnam EA, Carmical SG et al. Ten novel FBN2 mutations in congenital contractural arachnodactyly: delineation of the molecular pathogenesis and clinical phenotype. Human Mutations 2002; 19: 39-48.
158. Sotos JF, Dodge PR, Muirhead D et al. Cerebral gigantism in childhood: a syndrome of excessively rapid growth and acromegalic features and a non-progressive neural disorder. New England Journal of Medicine 1964; 271: 109-116.
159. Sotos JF. Overgrowth. Section V. Syndromes and other disorders associated with overgrowth. Clinical Pediatrics (Philadelphia) 1997; 36: 89-103.
160. Rao VH, Buehler BA & Schaefer GB. Accelerated linear growth and advanced bone age in Sotos syndrome is not associated with abnormalities of collagen metabolism. Clinical Biochemistry 1998; 34: 241-249.
161. Smith M, Fullwood P, Qi Y et al. No evidence for uniparental disomy as a common cause of Sotos syndrome. Journal of Medical Genetics 1997; 34: 10-12.
162. Lin AE, Liu Q, Mannheim GB & Darras BT. Exclusion of growth factor gene mutations as a common cause of Sotos syndrome. American Journal of Medical Genetics 2001; 98: 101-102.
163. Wit JM, Beemer FA, Barth PG et al. Cerebral gigantism (Sotos syndrome). Compiled data of 22 cases. Analysis of clinical features, growth and plasma somatomedin. European Journal of Pediatrics 1985; 144: 131-140.
164. Ambler GR, Cowell CT, Quigley CA & Silink M. Growth hormone hypersecretion in Sotos' syndrome? Acta Paediatrica 1993; 82: 214-216.
165. Agwu JC, Shaw NJ, Kirk J et al. Growth in Sotos syndrome. Archives of Disease in Childhood 1999; 80: 339-342.
166. Cole TR & Hughes HE. Sotos syndrome: a study of the diagnostic criteria and natural history. Journal of Medical Genetics 1994; 31: 20-32.
167. Cohen MM Jr, Neri G & Weksberg R. Sotos Syndrome. Overgrowth Syndromes pp 51-56. Oxford: Oxford University Press, 2002.
168. Schaefer GB, Bodensteiner JB, Buehler BA et al. The neuroimaging findings in Sotos syndrome. American Journal of Medical Genetics 1997; 68: 462-465.
169. Cohen MM Jr. Tumors and nontumors in Sotos syndrome. American Journal of Medical Genetics 1999; 84: 173-175.
170. Hersh JH, Cole TR, Bloom AS et al. Risk of malignancy in Sotos syndrome. Journal of Pediatrics 1992; 120: 572-574.
171. Cohen MM Jr, Neri G & Weksberg R. Neurofibromatosis. Overgrowth Syndromes pp 130-151. Oxford: Oxford University Press, 2002.
172. Sotos JF. Genetic disorders associated with overgrowth. Clinical Pediatrics (Philadelphia) 1997; 36: 39-49.
173. Topaloglu AK, Sansaricq C & Snyderman SE. Influence of metabolic control on growth in homocystinuria due to cystathionine B-synthase deficiency. Pediatric Research 2001; 49: 796-798.